MedTrace Logo

The Mutation Profile and Prognosis in AML With IDH1/2 Mutation

NCT07004816 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1015

Last updated 2025-11-18

No results posted yet for this study

Summary

Investigators have a prospective clinical cohort including 500 adult AML patients. And investigators have stored leukemia sample from these patients. In this program investigators will do mutation profile in these patients. Also, investigators will elucidate the incidence of IDH1/2 mutations in adult AML in China and elucidate the prognostic effect of IDH1/2 mutation in AML.

Conditions

Interventions

OTHER

Uncover mutation profiles

Uncover mutation profiles

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Eligibility

Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-21
Primary Completion
2020-03-24
Completion
2020-03-24

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07004816 on ClinicalTrials.gov